The Danish pharmaceutical firm said the move would put it in the best possible position to launch new medicines
Danish pharmaceutical firm Lundbeck will merge a number of subsidiaries and could cut up to 55 jobs in Europe as it streamlines its commercial structure.
The firm said it would simplify its structure in Europe by organising more than 30 affiliates into 10 ‘strong business units’.
Lundbeck said setting up such units in Europe would ‘improve competencies in areas such as market access, marketing and medical affairs’.
Activities will be aligned across countries, which will eliminate duplication of activities and minimise the general complexity of the business.
Lundbeck said the move would ‘put the company in the best possible position to successfully launch new medicines’. It follows the company’s establishment of a more flexible commercial organisation in Europe last year, which also saw the optimisation of its research and development activities.
We want the best possible set-up to ensure the transition of our product portfolio through successful launches of new medicines
In addition, the company said it would divide its commercial operations into six regions of Europe, US, Canada, Asia, Latin America and Middle East plus Global Distribution to ‘ensure full focus on growth markets’.
‘We want the best possible set-up to ensure the transition of our product portfolio through successful launches of new medicines. With this plan we will have the focus, the structure and the competencies in place to achieve that,’ said Ole Chrintz, Senior Vice President, International Markets and Europe at Lundbeck.
Lundbeck has informed the company’s European and Danish Works Council about the restructuring plans and the potential job cuts.